Structural MR and amyloid PET imaging have been proposed by the National Institute on Aging as methods to subdivide preclinical Alzheimer Disease (AD) into discrete stages of (1) amyloidosis, followed by (2) amyloidosis plus neurodegeneration, both of which precede (3) subtle cognitive decline, followed by the clinical progression to mild cognitive impairment (MCI) and AD dementia. The HASD Imaging Core will provide MR and PET support to the HASD Projects to test how these proposed stages relate to the transition for normal to impaired cognitive performance (Project 1), sleep disturbance (Project 2), and genetic analyses (Project 3). The following Specific Aims will be pursued: I. Combined PET-MR scanning for brain structure, function, and amyloid pathology. For the entire combined HASD and ADRC cohorts, we will perform brain MRI and florbetapir F18 (AV45) amyloid imaging every three years (200 participants/year). II. Provide data processing for these imaging tests, to include (2a) matched regional volumes, thicknesses, and quantitative PET analyses, (2b) quantitative individual longitudinal participant reports compared normative values generated by the cohort, and (2c) grouped regional reports based on classifications derived from the Projects and Cores. III. Generate an online accessible resource containing source imaging (DICOM), processed imaging, and clinical and biomarker characterization to facilitate data sharing outside of our institution, including contributions to the private-public partnership developed by JC Morris, HASD PI, and T. Benzinger, HASD Imaging Core Leader, with Avid/Lilly. This partnership allows funding for longitudinal MR and amyloid PET imaging for the entire cohort.
Core E: Imaging Project Narrative As instructed by the funding opportunity announcement for this application (PAR-13-329), only the Overall component contains a project narrative. Cores and projects were instructed not to include this section.
| Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558 |
| Joseph-Mathurin, Nelly; Su, Yi; Blazey, Tyler M et al. (2018) Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. Alzheimers Dement (Amst) 10:669-677 |
| Del-Aguila, Jorge L; Fernández, Maria Victoria; Schindler, Suzanne et al. (2018) Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline. J Alzheimers Dis 62:745-756 |
| Oxtoby, Neil P; Young, Alexandra L; Cash, David M et al. (2018) Data-driven models of dominantly-inherited Alzheimer's disease progression. Brain 141:1529-1544 |
| Mishra, Shruti; Blazey, Tyler M; Holtzman, David M et al. (2018) Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ?4 genotype. Brain 141:1828-1839 |
| Bonham, Luke W; Karch, Celeste M; Fan, Chun C et al. (2018) CXCR4 involvement in neurodegenerative diseases. Transl Psychiatry 8:73 |
| Schindler, Suzanne E; Gray, Julia D; Gordon, Brian A et al. (2018) Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement 14:1460-1469 |
| Wildburger, Norelle C; Gyngard, Frank; Guillermier, Christelle et al. (2018) Amyloid-? Plaques in Clinical Alzheimer's Disease Brain Incorporate Stable Isotope Tracer In Vivo and Exhibit Nanoscale Heterogeneity. Front Neurol 9:169 |
| Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2018) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord 32:10-17 |
| Babulal, Ganesh M; Chen, Suzie; Williams, Monique M et al. (2018) Depression and Alzheimer's Disease Biomarkers Predict Driving Decline. J Alzheimers Dis 66:1213-1221 |
Showing the most recent 10 out of 911 publications
